Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Short summary

Adding sitagliptin to usual care in type 2 diabetes patients with cardiovascular disease did not increase major adverse cardiovascular events, with a primary outcome occurring in 11.4% of the sitagliptin group vs. 11.6% of the placebo group over a median of 3.0 years.

AI-generated from the title and abstract; the full text is not read.